Search Immortality Topics:

Page 71«..1020..70717273..8090..»


Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Posted: March 18, 2024 at 2:36 am

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.

Here is the original post:
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Recommendation and review posted by G. Smith

NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

Posted: March 18, 2024 at 2:36 am

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, announces today its intention to broaden its market reach through a recently filed application for listing on the OTCQB® Venture Market (the "OTCQB") in the United States. Listing on the OTCQB is subject to approval of the OTC Markets Group.

Read more from the original source:
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

Recommendation and review posted by G. Smith

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

Posted: March 18, 2024 at 2:36 am

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”), one notifying the Company (the “MVLS Notice”) that for the last 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “Market Value Standard”), and the other notifying the Company (the “MVPHS Notice”) that for the last 30 consecutive business days, the Company’s Market Value of Publicly Held Shares (“MVPHS”) was below the minimum of $15 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Standard”).

Read the original:
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

Recommendation and review posted by G. Smith

Financière de Tubize – Annual report 2023

Posted: March 18, 2024 at 2:36 am

FINANCIERE DE TUBIZE SA/NV

Originally posted here:
Financière de Tubize - Annual report 2023

Recommendation and review posted by G. Smith

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Posted: March 18, 2024 at 2:36 am

Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors

See the original post:
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Recommendation and review posted by G. Smith

Idorsia and Viatris successfully close the transaction for the global research and development collaboration

Posted: March 18, 2024 at 2:36 am

Ad hoc announcement pursuant to Art. 53 LR

Excerpt from:
Idorsia and Viatris successfully close the transaction for the global research and development collaboration

Recommendation and review posted by G. Smith


Page 71«..1020..70717273..8090..»